Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts
Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR trial for zorevunersen in Dravet syndrome met enrollment targets with zero dropouts. The FDA granted breakthrough therapy designation. The study will assess seizures and Vineland-3 cognitive and behavioral endpoints. Stoke plans a rolling NDA start in Q1 2027, completing in Q3 2027.
How this was made
The 30-second read
Why it matters
The disclosed operational milestone (enrollment target met, zero dropouts) lowers execution risk and strengthens confidence in the company’s stated regulatory timeline for a rolling NDA submission starting in Q1 2027.
Market read
Traders may reprice near-term probability of successful trial completion and the credibility of the 2027 FDA submission plan, ahead of the next EMPEROR update.
What to watch
The receptive communication endpoint target (2 to 3 points) and the FDA pre-NDA meeting could still introduce label or data requirements that materially affect timelines and commercial expectations.
Background
Stoke is running the EMPEROR Phase III study of zorevunersen for Dravet syndrome, with seizure-focused primary endpoints and Vineland adaptive behavior assessments for cognitive and behavioral outcomes.
Ticker impact
Stoke says its EMPEROR Phase III Dravet trial topped enrollment targets with zero dropouts and will update near end of Q3.
Likely positive near-term sentiment, with follow-through tied to the end-of-Q3 EMPEROR update and eventual pre-NDA/NDA milestones.
The article provides concrete trial-operational progress (enrollment target met, no dropouts) plus a specific regulatory timeline (rolling NDA start Q1 2027, complete Q3 2027), which can re-rate probability of success and timeline credibility.
Market effects
Supports sentiment for antisense oligonucleotide and rare-disease biotech execution, especially for CNS indications with behavioral endpoints.
Primarily US biotech sentiment; international interest may rise given the Biogen partnership for ex-North America territories.
Limited direct global macro impact, but reinforces global rare-disease development confidence in gene-modulation approaches.
Counterpoint
Enrollment success does not guarantee efficacy; the article emphasizes endpoints and prior open-label examples rather than new Phase III efficacy results.
Key entities
- companyStoke Therapeutics
Clinical-stage biopharmaceutical developing zorevunersen for Dravet syndrome using its TANGO platform.
- drugzorevunersen
Antisense oligonucleotide therapy for Dravet syndrome; FDA granted breakthrough therapy designation.
- clinical_trialEMPEROR study
Phase III trial with seizure and Vineland-3 behavioral endpoints; company expects an update near end of Q3.
- companyBiogen
Partner for territories outside North America for zorevunersen commercialization and capabilities.
